Figure 2. Adjusted Odds Ratios for Adherence to Glucagon-Like Peptide-1 Receptor Agonist (GLP1-RA) and Sodium-Glucose Cotransporter 2 Inhibitor (SGLT2i) Therapies by Co-payment Level.

The sequential logistic regression modeling approach considered patient demographics only (model 1), then added medical comorbidities (model 2) and patient socioeconomic factors and index prescription fill year (model 3). Adjusted odds ratios (AORs) of adherence compared a proportion of days covered of more than 80% across co-payment levels. Squares indicate AORs, with horizontal lines representing 95% CIs. Low co-payment was defined as less than $10; medium, $10 to less than $50; and high, $50 or greater.